0.00Open0.25Pre Close0 Volume201 Open Interest2.50Strike Price0.00Turnover135.88%IV17.77%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.4758Delta0.6300Gamma11.68Leverage Ratio-0.0092Theta0.0004Rho5.56Eff Leverage0.0019Vega
MediciNova Stock Discussion
13 mins ago
Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd
MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data
📊⚡️📊
MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova (NASDAQ: MNOV) announced it will receive monetary damages following the settlement of Sanofi-Novartis litigation. The company plans to use this non-dilutive fundingto support ongoing clinical development programs, particularly focusing on their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. The settlement validates MediciNova's in...
No comment yet